Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified February 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT02077933
First received: February 28, 2014
Last updated: NA
Last verified: February 2014
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: August 2016
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)